Preclinical Studies of PT199, a Humanized mAb That Fully Inhibits Both Membrane Bound & Soluble Serum CD73

Time: 11:15 am
day: Day Two


• Discussing why the full inhibition of the enzyme activity from both membrane and soluble CD73 is crucial to achieve clinical activity

• Exploring how the PD response/biomarker may guide the selection of targeted indications and/or patients